Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + cisplatin + vinorelbine
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Cetuximab + cisplatin + vinorelbine is a combination regimen used primarily as first-line treatment for advanced non-small-cell lung cancer (NSCLC) expressing epidermal growth factor receptor (EGFR). Cetuximab is a monoclonal antibody that targets the EGFR, inhibiting its signaling and thereby reducing tumor cell proliferation. Cisplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. Vinorelbine is a vinca alkaloid that disrupts microtubule formation, inhibiting mitosis. The combination has demonstrated improved response rates and survival compared to chemotherapy alone, with an acceptable safety profile[1][3][5].
- Brand names
- ErbituxPlatinolNavelbine
- Other names
- cetuximab + cisplatin + vinorelbine
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on cetuximab + cisplatin + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + cisplatin + vinorelbine.